Tracking infections and quality of life in blood cancer patients with weakened immunity
Develops a patient questionnaire for infection symptoms in adults with leukemia or myeloma.
Plain-language title generated from the registry record
Registry title: Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
Key facts
- Where
- Berlin and Garmisch-Partenkirchen, GermanySee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma or chronic lymphocytic leukemia who also have secondary immunodeficiency. Participants fill in daily symptom questionnaires online.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Multiple myeloma or chronic lymphocytic leukemia with secondary immunodeficiency (for example recurrent infections, infections needing hospital treatment, low antibody levels, or low white blood cell counts)
Main reasons for not taking part
- Cannot join without access to an internet device such as a computer, tablet or smartphone
- Cannot join if not German-speaking
Read by machine on 12 November 2026.
Where in Germany
- Onkologischer Schwerpunkt am Oskar-Helene-HeimBerlin, GermanyContact: Markus Schuler, Priv.-Doz. Dr. med.Not yet recruiting
- Klinikum Garmisch-PartenkirchenGarmisch-Partenkirchen, GermanyContact: Till Seiler, Dr. med.Not yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Medical University Innsbruck
- Trial code
- NCT06821880
- Record updated
- 12 February 2025
- Original description
The goal of this observational study is to improve the treatment of hematological patients with secondary immunodeficiency (SID) by developing a patient-reported outcome (PRO) instrument to detect clinically diagnosed infections. The study focuses on adults diagnosed with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) who are at increased risk of infections due to SID.Read full original descriptionShow less
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
The goal of this observational study is to improve the treatment of hematological patients with secondary immunodeficiency (SID) by developing a patient-reported outcome (PRO) instrument to detect clinically diagnosed infections. The study focuses on adults diagnosed with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) who are at increased risk of infections due to SID.
The main questions it aims to answer are:
1. Can a newly developed PRO screening tool for infection-related symptoms reliably detect infections in patients with SID? 2. How does the health-related quality of life change over the treatment course
Participants will:
* Complete daily electronic PRO questionnaires (ePRO) to monitor infection-related symptoms * Complete ePRO health-related quality of life questionnaires every 1.5 months * Participate in study visits every three months to ensure documentation of clinical data
Inclusion: Adult patient (>=18 years of age); Access to an internet device (e.g., personal computer or tablet to use a web-based platform, or smartphone where the study app can be installed - all common iOS and Android systems); German-speaking; Diagnosis of multiple myeloma or chronic lymphocytic leukemia; Secondary immunodeficiency (defined as: recurrent infections, infections requiring inpatient treatment, hypogammaglobulinemia, neutropenia and/or lymphopenia on differential blood cell counts, deficit in lymphocyte subsets as assessed by flow cytometry).